Sarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.
Sarah Elizabeth Yentz, MD
Advertisement
Articles by Sarah Elizabeth Yentz, MD
Sarah Elizabeth Yentz, MD, discusses how she decides between an immunotherapy agent plus a TKI combination vs 2-agent immunotherapy for patients with renal cell carcinoma.
Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.
Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.
Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr Yentz on Treatment Decisions for Patients With Kidney CancerPublished: August 17th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5